Axiom Space has announced its crew for its second commercial space launch. Image via Axiom

A Houston-based company is making history with its next commercial flight mission.

Axiom Space announced that Axiom Mission 2, or Ax-2, the second all-private mission to the International Space Station, will have members of the Kingdom of Saudi Arabia's national astronaut program aboard. It will also be the first private mission commanded by a woman: Peggy Whitson, Axiom's director of human spaceflight and former NASA astronaut.

“Axiom Space’s second private astronaut mission to the International Space Station cements our mission of expanding access to space worldwide and supporting the growth of the low-Earth orbit economy as we build Axiom Station,” says Michael Suffredini, president and CEO of Axiom Space, in a news release. “Ax-2 moves Axiom Space one step closer toward the realization of a commercial space station in low-Earth orbit and enables us to build on the legacy and achievements of the ISS, leveraging the benefits of microgravity to better life on Earth.”

Expected to launch this spring, it's the second ISS mission for the commercial aerospace company founded in 2016. Ax-2 Mission Specialists Ali Alqarni and Rayyanah Barnawi will be the first Saudi astronauts to visit the ISS after Axiom and the Kingdom of Saudi Arabia reached an agreement in 2022. With this mission, KSA will become only the sixth country to have two astronauts working on the ISS at the same time.

“This flight is an integral milestone of a comprehensive program aiming to train and qualify experienced Saudis to undertake human spaceflight, conduct scientific experiments, participate in international research, and future space-related missions contributing to the Kingdom’s Vision 2030,” reads a statement from the country.

Pilot John Shoffner, a businessman and aviator from Knoxville, Tennessee, with over 8,500 hours of flying under his belt, is the crew's fourth and final member.

A SpaceX Falcon 9 rocket will launch the Ax-2 crew aboard a SpaceX Dragon spacecraft to the ISS from NASA’s Kennedy Space Center in Florida, and they will spend 10 days on the mission. The mission is targeted for launch in the spring of 2023, and will be the first private space mission to include both private astronauts and astronauts representing foreign governments.

Whitson, a Rice university alum, will add to her deep resume, which also includes adding even more space time to the standing record for the longest cumulative time of any astronaut in the history of the U.S. space program.

“I am honored and excited to lead the Ax-2 crew and mission,” Whitson says in a statement. “The space station is a vital platform for all types of research. We at Axiom Space are committed to working with NASA to open the door for private citizens to contribute to and advance the groundbreaking research aboard the station, forging the path for us to operate, live and work abroad Axiom Station.”

Axiom aims to build its own commercial space station to launch in late 2025. Axiom’s first mission completed last April, and the company, deemed a unicorn with a $1 billion valuation, has raised $200 million, including a $130 million series B round in 2021.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”